fda compounding semaglutide crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Despite FDA crackdown, unapproved GLP-1s
Description
Psychiatry 64, 327337
From the Metabolic Syndrome to NAFLD or Vice Versa
lipid panels are paired with hepatic enzymes and indices of de novo lipogenesis
Additionally, one study reported increased dysgeusia (loss of taste), throat tightness and irritation, dysphagia (difficulty swallowing), and dysphonia (difficulty speaking) ( Khan et al
The data are expressed as the mean standard deviation (SD)
